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Despite  a wide  array  of safe  and  effective  vaccines  in use globally,  with  major  impacts  on health  world-
wide,  the WHO  Strategic  Advisory  Group  of  Experts  (SAGE)  on Immunization  has  been  repeatedly
confronted  with  reports  of  hesitancy  towards  accepting  speciﬁc  vaccines  or  vaccination  programmes.
This  paper  summarizes  the rationale  for a SAGE  review  of  the  issue  of  vaccine  hesitancy,  its impact  andaccination hesitancy
accine hesitancy
AGE
HO
ways  to address  it,  and  the  convening  of  a Vaccine  Hesitancy  Working  Group  in  March  2012  to prepare
for  the SAGE  review.  It describes  the methods  used  and  mode  of  operations,  and  advances  in the  rela-
tively  new  ﬁeld  of research  on vaccine  hesitancy.  It further  elaborates  and  references  the work  conducted,
including  a series  of products,  conclusions  and recommendations  that emerged  from  the  SAGE  review in
October  2014.
©  2015  Published  by  Elsevier  Ltd. This  is  an  open  access  article  under  the  CC  BY license  (http://. Background
The Strategic Advisory Group of Experts (SAGE) on Immuniza-
ion, established by the Director-General of the World Health
rganization (WHO) in 1999, provides guidance on the work of
HO concerning vaccines and immunization, and is the principal
dvisory group to WHO  in this ﬁeld. It is charged with advising WHO
n overall global policies and strategies, ranging from vaccines
nd technology, research and development, to implementation of
mmunization and its linkages with other health interventions.
AGE is concerned with all vaccine-preventable diseases as well
s cross-cutting issues related to immunization. SAGE Working
roups are convened on an ad hoc basis to assemble and review the
vailable data on speciﬁc topics and propose draft conclusions and
ecommendations for SAGE’s consideration during its bi-annual
eetings.
Since its establishment, SAGE has been repeatedly confronted
ith reports of decreased acceptance of vaccines and/or immuniza-
ion programmes by individuals or communities. This recurrent
heme, spanning different vaccines and immunization issues, has
merged in both developed and developing countries. Presented
ith a report from the Global Advisory Committee on Vaccine
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Safety, in June 2001 SAGE noted that although scientiﬁc reports
stated that there was  no evidence of adverse events following
immunization (AEFI), the public remained unsatisﬁed and wanted
to be convinced that vaccines had been proven safe. A discrepancy
between scientiﬁc evidence and perception of risk and difﬁculties
in communication were highlighted. SAGE then endorsed the pro-
posal for the development of a communication strategy to address
public concern about AEFI in general, although it was acknowl-
edged that there would always be a marginal yet inﬂuential group
of people who would not trust information on immunization [1].
In the SAGE June 2002 report, thiomersal safety concerns, which
were noted to be mostly driven by perceptions rather than by estab-
lished scientiﬁc facts, were raised [2]. In November 2006, the WHO
Regional Ofﬁce for Europe (WHO/EURO) reported that, in response
to negative publicity about immunization, it was prioritizing infor-
mation and advocacy initiatives such as the expansion of the Global
Vaccine Safety Net initiative and European Immunization Week
[3]. The November 2008 SAGE report emphasized that misinforma-
tion about vaccine safety and AEFI had had negative effects during
recent measles and rubella vaccination campaigns. Mistrust and
fear of vaccines and immunization have led to a lack of support
by some health professionals. Politicization of vaccination recom-
mendations and decisions, as well as commercial interests of the
pharmaceutical industry, have further exacerbated the situation in
some countries.
The need for a methodical and proactive communication
strategy to respond to misinformation and anti-immunization
activities was recognized by WHO/EURO [4]. Particular challenges
Y license (http://creativecommons.org/licenses/by/3.0/).
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o eliminating measles including a lack of political and societal
upport for the goal, propaganda by anti-vaccine groups, contrary
eligious and philosophical beliefs, competing health priorities, and
roblems created by the reform of health systems in some east-
rn European countries were recognized by SAGE in October 2009
5]. The October 2010 report stated that WHO/EURO had also been
sked to use the European immunization week as a platform for
ncreasing public awareness of the beneﬁts of immunization and
ountering the false messages disseminated by anti-vaccination
ovements [6]. In April 2011, continued non-compliance with vac-
ination in several areas in Nigeria at high risk of wild poliovirus
ransmission was noted as a cause of concern by SAGE [7]. In
ovember 2011 SAGE acknowledged that it would be crucial to
ddress vaccine hesitancy in India, classiﬁed as a polio-endemic
ountry at that time, as hesitancy was hampering the country’s
fforts to eliminate polio [8].
Given the continuous reappearance of a broad range of issues
elated to mistrust and non-acceptance of vaccines and the
oncerns expressed by different countries, the use of effective com-
unication about vaccines with vaccine-hesitant populations was
isted in April 2011 as a priority topic for SAGE to address [7]. SAGE
xpressed concern that the way forward to tackle hesitancy was  not
lear and felt that the global challenge of vaccine hesitancy, which
osed a major threat to the integrity and acceptance of vaccines
nd immunization programmes worldwide, should be assessed and
ealt with. Based on these concerns about vaccine hesitancy, its
mpact on vaccine uptake rates and the performance of national
mmunization programmes, SAGE established the SAGE Working
roup on Vaccine Hesitancy in March 2012 with the following
erms of reference [9].
. Terms of reference
Prepare for SAGE a review and advice on how to address vaccine
hesitancy and its determinants.
Deﬁne vaccine hesitancy and its scope.
Undertake a review of vaccine hesitancy in different settings
including its context-speciﬁc causes, its expression and its
impact.
Suggest one or several indicator(s) of vaccine hesitancy that could
be used to monitor progress in the context of the Decade of Vac-
cines Global Vaccine Action Plan.
At global, regional and national levels:
◦ Perform a landscape analysis of who/what organizations are
working on this issue in various settings/countries;
◦ Identify existing activities and strategies that have had or could
have a positive impact including examination of successful
strategies that are not speciﬁcally related to vaccines or even
medicines;
◦ Identify strategies and activities that did not work well;
◦ Identify new activities and strategies that could have a positive
impact;
◦ Prioritize existing and new activities/strategies based on an
assessment of their potential impact;
◦ Outline the speciﬁc role of WHO  in addressing vaccine hesi-
tancy; and
◦ Identify the speciﬁc role of regional and country advisory com-
mittees.
. Working Group on Vaccine Hesitancy and its SecretariatA total of 11 international experts actively participated in the
roceedings and deliberations of the Working Group. Following
n open call for nominations, the experts were selected based on
heir experience in the ﬁeld of vaccine hesitancy and to represent3 (2015) 4157–4160
a wide array of expertise including social anthropology, communi-
cation and media, immunization programme delivery, knowledge
of vaccination and experience in addressing vaccine hesitancy at a
community level. Broad representation was  assured from all WHO
regions and from diverse contexts and backgrounds, as well as bal-
anced membership from developing and developed countries. As
for all SAGE working groups, transparent processes for assessment
of conﬂicts of interest were put in place. Potential conﬂicts of inter-
est of members were assessed and made publicly available on the
WHO website [9].
The Working Group was supported by a joint WHO–UNICEF
Secretariat, which included several departments, not only those
directly involved with immunization, at both the headquarters and
regional levels.
4. Methods and activities
The general approach of the Working Group on Vaccine Hes-
itancy was guided by the terms of reference set by SAGE. Initial
deliberations of the Working Group speciﬁed the requested deliver-
ables and identiﬁed appropriate methods. These methods included:
1) Conducting relevant de novo systematic literature searches of
evidence on vaccine hesitancy in order to explore vaccine hesi-
tancy in different settings including its context-speciﬁc causes,
its expression and its impact: studies to be included were peer-
reviewed publications, gray literature, reviews of published
systematic reviews, and ﬁeld reports;
2) Reviewing and assessing models characterizing vaccine hesi-
tancy developed by different organizations;
3) Discussing personal observations reported from the ﬁeld by dif-
ferent organizations and Working Group members;
4) Conducting an immunization managers’ survey of vaccine hesi-
tancy;
5) Conducting a de novo systematic literature search to gener-
ate data on vaccine hesitancy intervention strategies, including
review of peer-reviewed studies and gray literature. This review
also took into consideration successful strategies from beyond
the ﬁeld of immunization, within the area of reproductive
health. The quality of the retrieved evidence was  assessed using
the GRADE methodology. A literature review of existing system-
atic reviews complemented the retrieved evidence;
6) Compiling vaccine hesitancy survey questions extracted from
the published and gray literature and developing questions de
novo with input from the Working Group members;
7) Developing and pilot testing of vaccine hesitancy indicators
in the WHO–UNICEF Joint Reporting Form (JRF) in 2012 and
2013 and at Inter-country Support Team South, East and Central
African Regional Immunization Managers’ meetings in 2013, in
view of the Global Vaccine Action Plan Strategic Objective 2 “that
individuals and communities understand immunization as their
right and responsibility”; and
8) Consultations to discuss hesitancy and its impact with the
Global Polio Eradication Initiative (GPEI), United States National
Vaccine Advisory Committee (NVAC), communications and mar-
keting experts from industry, and other working groups and
advisory committees, such as the SAGE Global Vaccine Action
Plan (GVAP) Working Group, the SAGE Measles and Rubella
Working Group, the Global Advisory Committee on Vaccine
Safety (GACVS), and the Immunization and Vaccine Related
Implementation Research Advisory Committee (IVIR-AC).Beyond the Working Group’s Secretariat, diverse departments
in WHO  and UNICEF were asked to identify additional staff
from their departments able to contribute to speciﬁc discussions.
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ther organizations not involved in immunization were also
onsulted including programmes, academic and research groups
orking on related topics. Attempts were made to draw upon
xperiences from beyond the ﬁeld of immunization and beyond
he health sector that relate to hesitancy/refusal to accept certain
ervices and/or products or behavioural changes.
Discussions took place via email, monthly conference calls and
hree in-person meetings of the Working Group.
. Processes
The Working Group began its work in March 2012 and continued
ntil the ﬁnal presentation to SAGE in October 2014.
Two in-person meetings in October 2012 and February 2013,
n addition to the monthly teleconferences, facilitated the devel-
pment of a deﬁnition of vaccine hesitancy, a workable model of
actors impacting vaccine hesitancy [10] and indicators of vaccine
esitancy [11], which were pilot tested in the WHO  Region of the
mericas and the European Region in the 2013 JRF. By April 2013,
he commissioned systematic review on vaccine hesitancy [12] had
een ﬁnalized, and based on the retrieved evidence, the systematic
eview on interventions to address vaccine hesitancy had been ini-
iated. A landscape analysis of organizations working on vaccine
esitancy was conducted.
These products and the preliminary results, as well as an interim
eport on the status of the proceedings, were presented to SAGE in
pril 2013 [13].
SAGE endorsed the effort to review successful interventions in
ealth-related ﬁelds beyond immunization, aiming at improving
onﬁdence and increasing demand for vaccination, and supported
he development of diagnostic tools to identify the context-speciﬁc
ause(s) of hesitancy and to differentiate hesitancy from the many
ther reasons why children are not vaccinated or under-vaccinated,
s such tools would help guide strategies to address the underlying
auses. SAGE noted that the proposed indicators on vaccine hesi-
ancy were currently being ﬁeld-tested and that recommendations
hould be developed regarding demand creation and proactive
nterventions. SAGE recommended close linkages and interaction
ith key WHO  and UNICEF initiatives to address the unvaccinated
r under-vaccinated groups and relevant interventions.
Following the SAGE interim recommendations, the Working
roup carried out the Immunization Programme Managers’ Sur-
ey in 2013[14] including interviews with selected programme
anagers, and revised the deﬁnition of vaccine hesitancy [10].
Based on the matrix of determinants of vaccine hesitancy, in
esponse to requests from countries, a standard list of survey
uestions was prepared by the Working Group with questions
eveloped de novo or retrieved from published literature, acknowl-
dging that few of these questions have been validated, and that
one of the questions had been validated in settings other than
igh-income countries [11]. The systematic review on strategies
as ﬁnalized prior to the October 2014 SAGE meeting [15]. The
orking Group reviewed the 2013 Guide to Tailoring Immu-
ization Programmes (TIP) developed by WHO/EURO. The TIP
ramework is based on evidence from behavioural economics, the
edical humanities, psychology, and neuroscience. It may  be a use-
ul tool in understanding and addressing vaccine hesitancy, though
urther evaluation is needed [16].
A ﬁnal in-person meeting of the Working Group took place in
ecember 2013. This meeting focused on interaction with partners
nd reaching out to other initiatives to examine their experiences
nd how these might be relevant in addressing vaccine hesi-
ancy and creation of demand. In addition to the Working Group
embers, participants attending this meeting included WHO  and
NICEF technical staff from headquarters, regional and country3 (2015) 4157–4160 4159
ofﬁces and marketing experts from industry via the International
Food & Beverage Alliance (IFBA) [17].
The Working Group discussed the ﬁndings and lessons learned
from each of the initiatives and incorporated the conclusions in
their deliberations and recommendations based on the retrieved
evidence [18]. Final Working Group conclusions and recommenda-
tions as well as the various developed or reviewed products were
reviewed and endorsed by SAGE in October 2014 [19].
6. Discussion
The iterative approach followed by the Working Group through-
out its work has both strengths and limitations. The inclusion of a
diverse group of experts from different disciplines proved to be very
important for critical discussions of the nuances revealed in the
reviews, surveys and consultations. Representation of geographic
and socioeconomic diversity from all WHO  regions was  necessary
in order to understand the issues from a global perspective, with-
out which the report could have placed undue emphasis on ﬁndings
from high-income countries, such as those retrieved from the sys-
tematic review of evidence.
The main limitation of the approach was  the context in which
the work was  carried out. This was  a period in which much new
information was  coming forward and the understanding of vaccine
hesitancy was  evolving. Having a clear and practical accepted deﬁ-
nition for vaccine hesitancy was  critical for the systematic reviews
and consultations, so that like could be compared with like. As the
term ‘vaccine hesitancy’ was still emerging, this presented some
initial problems for the Working Group, as reﬂected in the lengthy
process to reach the accepted deﬁnition.
The recognition that vaccine hesitancy is complex with many
different determinants that vary with context, vaccine, setting and
time infers that it is unlikely that any single strategy would be
effective in addressing all determinants of vaccine hesitancy.
The systematic reviews, studies and consultations revealed
many gaps in knowledge about vaccine hesitancy, with a paucity of
work in particular from middle and low-income settings, but also
revealed useful strategies for moving forward.
The volume of work carried out by the Working Group was  nec-
essarily compressed in the report to SAGE and the related annexes
[20]. This supplement on vaccine hesitancy is intended to present
the issues and ﬁndings that were reported to SAGE and expand the
audience for this information, in order to raise awareness of vac-
cine hesitancy as an important modern public health problem, in
a readily accessible publication for the public health and scientiﬁc
communities and the general public.
As was  emphasized by SAGE, ongoing evaluation of the deliv-
erables developed by the Working Group is essential. And beyond
the scope of the SAGE review, validation of the developed tools and
assessment of future and current research and strategies are also
needed.
These contributions to understanding, deﬁning and commu-
nicating on the topic are seen as an initial step in tackling the
continuing and evolving challenges in the ﬁeld of vaccine hesi-
tancy. The conclusions and recommendations endorsed by SAGE
in October 2014 [18] may  contribute to efforts to address vaccine
hesitancy, particularly by national immunization programmes in
all regions of the world when considering the introduction of new
vaccines or counteracting the dwindling uptake of well-established
vaccines.Conﬂict of interest statements
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